WHAT IS CLAIMED IS:

1. An immunogenic composition comprising: a modified, live bovine viral diarrhea virus type 1b (BVDV-1b), and a veterinary-acceptable carrier.

2. The immunogenic composition of claim 1, wherein the modified, live bovine viral diarrhea virus is a cytopathic BVDV-1b virus.

3. The immunogenic composition of claim 1, further comprising one or more of a parainfluenza virus Type 3 (PI_3), a bovine respiratory syncytial virus (BRSV), a bovine herpes virus (BHV-1), a bovine viral diarrhea virus Type 1a (BVDV-1a), a bovine viral diarrhea virus Type 2 (BVDV-2), or an infectious bovine rhinotracheitis (IBR) virus, or any combination thereof; or one or more viral-specific antigens obtained therefrom.

4. The immunogenic composition of claim 1, further comprising a modified, live IBRV, a modified, live BRSV, a modified, live BHV-1, a modified, live BVDV Type 1a, a modified, live BVDV Type 2, or a modified, live PI_3, or a combination thereof.

5. The immunogenic composition of claim 1, further comprising an adjuvant.

6. The immunogenic composition of claim 1, further comprising an immunologically effective amount of at least a first antigen.

7. The immunogenic composition of claim 6, wherein the at least a first antigen is specific for an organism selected from the group consisting of *Actinobacillus, Actinomyces, Bacillus*, *Bordetella, Brachyspira, Campylobacter, Clostridium*, *Ehrlichia, Erysipelothrix, Escherichia, Histophilus*, *Leptospira, Listeria*,

Mannheimia, *Moraxella*, *Mycobacterium*, *Mycoplasma*, *Pasteurella*, *Salmonella*, and *Streptococcus*, or a combination thereof.

8. The immunogenic composition of claim 6, wherein the at least a first antigen is inactivated.

9. The immunogenic composition of claim 1, formulated as a mammalian vaccine.

10. The immunogenic composition of claim 9, formulated as a bovine vaccine.

11. A vaccine comprising a prophylactically-effective amount of the immunogenic composition of claim 1, and an adjuvant.

12. The vaccine of claim 11, further comprising an immunologically-effective amount of a least one microbial pathogen-specific antigen.

13. An immunologically-effective amount of a composition comprising a plurality of BVDV Type 1b modified, live viruses, and a veterinary-acceptable carrier for use in inducing a bovine viral diarrhea virus Type 1b (BVDV-1b)-specific immune response in a mammal.

14. The composition of claim 13, wherein the composition is to be administered to the mammal prophylactically.

15. The composition of claim 13, wherein administration of the composition provides a therapeutic effect in the mammal.

16. The composition of claim 13, wherein the composition is to be administered orally, subcutaneously, parenterally, intramuscularly, or intranasally, or a combination thereof.

17. The composition of claim 13, wherein the composition contains from about 10^2 to about 10^{10} $TCID_{50}$ per dose of modified, live viruses.

18. A composition comprising a modified, live BVDV-1b virus and a veterinary-acceptable carrier for use in preventing shipping fever in an animal.

19. The composition of claim 18, wherein the composition further comprises an adjuvant.

20. The composition of claim 18, wherein the animal is infected by, or susceptible to infection from, a pestivirus.

21. The composition of claim 18, wherein the animal is a bovid.

22. A prophylactically- or therapeutically-effective amount of a composition comprising a modified, live BVDV-1b virus and a pharmaceutically-acceptable carrier for use in preventing, treating, managing, or ameliorating one or more symptoms of a disease caused by a pestivirus in an animal susceptible to pestivirus infection.

23. The composition of claim 22, wherein the composition further comprises an adjuvant.

24. The composition of claim 22, wherein the composition further comprises an immunogen derived from one or more of bovine rotavirus, BRSV, BHV-1, bovine coronaviruses, PI_3, bovine paramyxovirus, foot and mouth disease virus, BRV, BVDV-1a, BVDV-2, *Mannheimia haemolytica* type A1, *Mannheimia haemolytica* type A6, *Pasteurella multocida, Histophilus somni,* and *Mycoplasma bovis.*

25. The composition of claim 22, wherein the animal is a bovid.

26. A prophylactically-effective amount of a composition comprising a modified, live BVDV-1b virus and a pharmaceutically-acceptable carrier for use in protecting an animal against disease caused by BVDV-1b.

27. The composition of claim 26, wherein the composition contains from about 10^2 to about 10^{10} $TCID_{50}$ units per dose of modified, live BVDV-1b virus.

28. The composition of claim 26, wherein the amount of the composition to be administered to the animal is from about 0.1 to about 5.0 mL per dose.

29. The composition of claim 26, wherein the composition further comprises an immunogen derived from a Bovine Rhinotracheitis Virus, a Bovine Respiratory Syncytial Virus, or a Parainfluenza 3 Virus, or a combination thereof.

30. The composition of claim 26, wherein the disease is shipping fever, bovine respiratory disease complex, or bovine viral diarrhea.

31. Use of a modified, live BVBV-1b virus in the manufacture of a medicament for the induction of a bovine viral diarrhea virus Type 1b (BVBV-1b)-specific immune response in a mammal.

32. Use of a modified, live BVBV-1b virus in the manufacture of a medicament for the prevention of shipping fever.

33. Use of a modified, live BVBV-1b virus in the manufacture of a medicament for the prevention, treatment, management or amelioration of one or more symptoms of a disease caused by a pestivirus in an animal susceptible to pestivirus infection.

34. Use of a modified, live BVBV-1b virus in the manufacture of a medicament for the prevention of an animal against a disease caused by BVBV-1b.

35. The use of claim 34, wherein the disease is shipping fever, bovine respiratory disease complex, or bovine viral diarrhea.

THE CLAIMS:

WHAT IS CLAIMED IS:

1. An immunogenic composition comprising: a modified, live, attenuated bovine viral diarrhea virus type 1b (BVDV-1b); a modified, live, attenuated parainfluenza virus Type 3 (PI_3); a modified, live, attenuated bovine respiratory syncytial virus (BRSV); a modified, live, attenuated bovine herpes virus (BHV-1); a modified, live, attenuated bovine viral diarrhea virus Type 1a (BVDV-1a); a modified, live, attenuated bovine viral diarrhea virus Type 2 (BVDV-2), and a veterinary-acceptable carrier.

2. The immunogenic composition of claim 1, wherein the modified, live bovine viral diarrhea virus is a cytopathic BVDV-1b virus.

3. The immunogenic composition of claim 1, further comprising an immunologically effective amount of at least one additional antigen.

4. The immunogenic composition of claim 3, wherein the at least one additional antigen is an inactivated bacterium selected from the group consisting of *Actinobacillus, Actinomyces, Bacillus*, *Bordetella, Brachyspira, Campylobacter, Clostridium*, *Ehrlichia, Erysipelothrix, Escherichia, Histophilus*, *Leptospira, Listeria*, *Mannheimia*, *Moraxella*, *Mycobacterium*, *Mycoplasma*, *Pasteurella, Salmonella*, and *Streptococcus,* or a combination thereof.

5. A vaccine comprising a prophylactically-effective amount of the immunogenic composition of claim 1, and an adjuvant.

6. The vaccine of claim 5, further comprising an immunologically-effective amount of at least one microbial pathogen-specific antigen, wherein the microbial pathogen is selected from the group consisting of *Actinobacillus, Actinomyces, Bacillus*, *Bordetella, Brachyspira, Campylobacter, Clostridium*, *Ehrlichia,*

Erysipelothrix, Escherichia, Histophilus, Leptospira, Listeria, Mannheimia, Moraxella, Mycobacterium, Mycoplasma, Pasteurella, Salmonella, and *Streptococcus,* or a combination thereof.

7. A prophylactically-effective amount of a composition according to any one of claims 1-4, for use in preventing shipping fever in an animal.

8. The composition of claim 7, wherein the animal is infected by, or susceptible to infection from, a pestivirus.

9. A prophylactically- or therapeutically-effective amount of a composition according to any one of claims 1-4 for use in preventing, treating, managing, or ameliorating one or more symptoms of a disease caused by a pestivirus in an animal susceptible to pestivirus infection.

10. The composition of claim 7 or 9, wherein the animal is a bovid.

11. A prophylactically-effective amount of a composition according to any one of claims 1-4 for use in protecting an animal against shipping fever, bovine respiratory disease complex, or bovine viral diarrhea.

12. Use of a composition according to any one of claims 1-4 in the manufacture of a medicament for the induction of a bovine viral diarrhea virus Type 1b (BVBV-1b)-specific immune response in a mammal.

13. Use of a composition according to any one of claims 1-4 in the manufacture of a medicament for the prevention of shipping fever.

14. Use of a composition according to any one of claims 1-4in the manufacture of a medicament for the prevention, treatment, management or amelioration of one or more symptoms of a disease caused by a pestivirus in an animal susceptible to pestivirus infection.

15. Use of a composition according to any one of claims 1-4in the manufacture of a medicament for the prevention of an animal against a disease caused by BVBV-1b.

16. The use of claim 15, wherein the disease is shipping fever, bovine respiratory disease complex, or bovine viral diarrhea.